Clinical Trials Logo

Myelodysplastic Syndromes clinical trials

View clinical trials related to Myelodysplastic Syndromes.

Filter by:

NCT ID: NCT01211691 Suspended - Clinical trials for Myelodysplastic Syndrome (MDS)

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This is a global, multicenter, open-label, repeat-dose, Phase 1/2 study consisting of a Dose Escalation Phase (Phase 1) and a Cohort Expansion Phase (Phase 2). In both phases, KB004 will be administered by IV infusion once weekly as part of a 21-day dosing cycle.

NCT ID: NCT01010373 Suspended - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome (MDS) patients.

NCT ID: NCT00935090 Suspended - Lymphoma Clinical Trials

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Start date: September 2009
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

NCT ID: NCT00329498 Suspended - Clinical trials for Acute Myeloid Leukemia

L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes

Start date: May 1998
Phase: Phase 2
Study type: Interventional

To document therapeutic gain achieved by cyclic application of L-ascorbic acid (LAA) supplementation and depletion, while confirming safety and avoidance of clinically significant scurvy, in chemorefractory patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).